PRIMARY STUDY

Non-psychotropic Cannabis sativa L. phytocomplex modulates microglial inflammatory response through CB2 receptors-, endocannabinoids-, and NF-κB-mediated signaling

Key Findings:  The phytocomplex of Cannabis Sativa extract showed significantly more anti-inflammatory activity in activated microglial cells than isolated cannabidiol (CBD) and β-caryophyllene (CAR) at the same concentration. This study could lead to promising therapeutics in reducing neuroinflammatory and related diseases.

Type of Study:  Laboratory Study

Study Result:  Positive

Study Location(s):  Italy

Year of Pub:  2022


Cannabinoids Studied:  Cannabidiol (CBD), Cannabinoid (unspecified), Endocannabinoid (unspecified), Other Related Compounds

Phytocannabinoid Source:  Cannabis Flower derived

Chemotype:  Chemotype III

Terpenes Studied:  ß-Caryophyllene, Humulene

Receptors Studied:  CB2, PPAR - Gamma

Ligands Studied:  Pro-inflammatory cytokines

Route of Administration:  In vitro



Link to study